# Amlodipine + Olmesartan

## SEVIKAR 5/40mg

| TAH Drug Code      | [OSEV3](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=OSEV3                                                                                                                                                                                                  |
|:-------------------|:-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Management of hypertension, not recommended for initial therapy.                                                                                                                                                                                                       |
| Dosing             | Initial: 5/20 mg q24h. After 2 weeks of treatment, the dose can be increased to 10/40 mg q24h as needed (Max: 10/40mg). If blood pressure control is still not ideal, alternative treatments can be considered, such as increasing the dose of one or both components. |
| Hepatic Impairment | Dose adjustment required                                                                                                                                                                                                                                               |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                          |
| Contraindications  | Combined use of Sevikar and drugs containing aliskiren in patients with diabetes or renal insufficiency (GFR<60ml/min/1.73 m2). Known hypersensitivity to Sevikar or any of its components.                                                                            |
| Adverse Effects    | Peripheral edema (dose related: 18-26%), anaphylaxis, hypotension, nocturia, orthostatic hypotension, palpitations, pruritus, skin rash, urinary frequency.                                                                                                            |
| Pregnancy          | Human Data Suggest Risk in 2nd and 3rd Trimesters                                                                                                                                                                                                                      |
| Lactation          | No (Limited) Human Data - Probably Compatible                                                                                                                                                                                                                          |
| More Info          | [UpToDate](https://www.uptodate.com/contents/amlodipine-and-olmesartan-drug-information)                                                                                                                                                                               |

